暫時無法取得訂價和供貨情況
推薦產品
等級
pharmaceutical primary standard
API 家族
dexamethasone
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
[Na+].[Na+].[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1(F)[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@@H](C)[C@]4(O)C(=O)COP([O-])([O-])=O
InChI
1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1
InChI 密鑰
PLCQGRYPOISRTQ-FCJDYXGNSA-L
基因資訊
human ... NR3C1(2908)
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Dexamethasone sodium phosphate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
產品號碼
描述
訂價
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Repr. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
客戶也查看了
Anna Gonciarz et al.
Electrophoresis, 33(22), 3323-3330 (2012-10-26)
Plasma protein binding of drugs may have significant effect on its pharmacodynamic, toxicological and pharmacokinetic properties, since only the free drug can pass across biological membrane and get to its specific site of action. Many drugs show a high affinity
Amy E Cohen et al.
Ophthalmology, 119(1), 66-73 (2011-11-26)
Determine safe, effective, iontophoretic dose(s) of EGP-437 (dexamethasone phosphate formulated for iontophoresis) in patients with noninfectious anterior uveitis; evaluate systemic drug exposures. Prospective, phase I/II, multicenter, double-masked, parallel group, randomized clinical trial. Forty outpatients with anterior uveitis. Forty of 42
Philip A Bird et al.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 32(6), 933-936 (2011-07-05)
To measure dexamethasone concentrations in the plasma and perilymph of the human ear after intravenous (IV) and intratympanic (IT) administration and to compare these with previous studies with methylprednisolone. Patients were administered dexamethasone by the IT or IV routes approximately
Parawee Rattanakit et al.
International journal of pharmaceutics, 422(1-2), 254-263 (2011-11-22)
A novel extrusion printing system was used to create drug delivery structures wherein dexamethasone-21-phosphate disodium salt (Dex21P) was encapsulated within a biodegradable polymer (PLGA) and water soluble poly(vinyl alcohol) (PVA) configurations. The ability to control the drug release profile through
Andrew M McMillan et al.
BMJ (Clinical research ed.), 344, e3260-e3260 (2012-05-24)
To investigate the effectiveness of ultrasound guided corticosteroid injection in the treatment of plantar fasciitis. Randomised, investigator and participant blinded, placebo controlled trial. University clinic in Melbourne, Australia. 82 people with a clinical and ultrasound diagnosis of plantar fasciitis unrelated
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
